Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 23798558)

1.

Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues.

Kosanam H, Prassas I, Chrystoja CC, Soleas I, Chan A, Dimitromanolakis A, Blasutig IM, Rückert F, Gruetzmann R, Pilarsky C, Maekawa M, Brand R, Diamandis EP.

Mol Cell Proteomics. 2013 Oct;12(10):2820-32. doi: 10.1074/mcp.M112.023507. Epub 2013 Jun 24.

2.

Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.

Chan A, Prassas I, Dimitromanolakis A, Brand RE, Serra S, Diamandis EP, Blasutig IM.

Clin Cancer Res. 2014 Nov 15;20(22):5787-95. doi: 10.1158/1078-0432.CCR-14-0289. Epub 2014 Sep 19.

PMID:
25239611
3.

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.

Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP.

BMC Cancer. 2013 Sep 3;13:404. doi: 10.1186/1471-2407-13-404.

4.

Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients.

Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, Han JX.

BMC Cancer. 2008 Aug 16;8:241. doi: 10.1186/1471-2407-8-241.

5.

Serum biomarker panels for the detection of pancreatic cancer.

Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, Langmead CJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE.

Clin Cancer Res. 2011 Feb 15;17(4):805-16. doi: 10.1158/1078-0432.CCR-10-0248.

6.

Development of serum parameters panels for the early detection of pancreatic cancer.

Zhang P, Zou M, Wen X, Gu F, Li J, Liu G, Dong J, Deng X, Gao J, Li X, Jia X, Dong Z, Chen L, Wang Y, Tian Y.

Int J Cancer. 2014 Jun 1;134(11):2646-55. doi: 10.1002/ijc.28584. Epub 2013 Nov 19.

PMID:
24615168
7.

Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.

Wang X, Li Y, Tian H, Qi J, Li M, Fu C, Wu F, Wang Y, Cheng D, Zhao W, Zhang C, Wang T, Rao J, Zhang W.

BMC Cancer. 2014 Aug 8;14:578. doi: 10.1186/1471-2407-14-578.

8.

Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.

Chen J, Chen LJ, Xia YL, Zhou HC, Yang RB, Wu W, Lu Y, Hu LW, Zhao Y.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1117-27. doi: 10.1007/s00432-013-1422-4. Epub 2013 Apr 2.

PMID:
23546595
9.

Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas.

Qi T, Han J, Cui Y, Zong M, Liu X, Zhu B.

J Clin Pathol. 2008 Jan;61(1):49-58. Epub 2007 Apr 5.

PMID:
17412869
10.

Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma.

Chung JC, Oh MJ, Choi SH, Bae CD.

ANZ J Surg. 2008 Apr;78(4):245-51. doi: 10.1111/j.1445-2197.2008.04429.x.

PMID:
18366394
11.

Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.

Jin A, Xu Y, Liu S, Jin T, Li Z, Jin H, Lin L, Lin Z.

Exp Mol Pathol. 2014 Feb;96(1):54-60. doi: 10.1016/j.yexmp.2013.11.003. Epub 2013 Nov 18.

PMID:
24263054
12.

Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus.

Kolb A, Rieder S, Born D, Giese NA, Giese T, Rudofsky G, Werner J, Büchler MW, Friess H, Esposito I, Kleeff J.

Cancer Biol Ther. 2009 Aug;8(16):1527-33. Epub 2009 Aug 13.

13.

Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.

Parikh DA, Durbin-Johnson B, Urayama S.

J Gastrointest Cancer. 2014 Mar;45(1):74-9. doi: 10.1007/s12029-013-9563-x.

PMID:
24272911
14.

Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma.

Chen J, Chen LJ, Yang RB, Xia YL, Zhou HC, Wu W, Lu Y, Hu LW, Zhao Y.

Med Oncol. 2013;30(2):583. doi: 10.1007/s12032-013-0583-y. Epub 2013 Apr 23.

PMID:
23609192
15.

Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.

Hocker JR, Postier RG, Li M, Lerner MR, Lightfoot SA, Peyton MD, Deb SJ, Baker CM, Williams TL, Hanas RJ, Stowell DE, Lander TJ, Brackett DJ, Hanas JS.

Cancer Lett. 2015 Apr 10;359(2):314-24. doi: 10.1016/j.canlet.2015.01.035. Epub 2015 Jan 28.

PMID:
25637792
16.

PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma.

Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, Newsome G, Goldenberg DM.

Cancer. 2013 Feb 1;119(3):522-8. doi: 10.1002/cncr.27762. Epub 2012 Aug 16.

17.

Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.

Shaw VE, Lane B, Jenkinson C, Cox T, Greenhalf W, Halloran CM, Tang J, Sutton R, Neoptolemos JP, Costello E.

Mol Cancer. 2014 May 20;13:114. doi: 10.1186/1476-4598-13-114.

18.
19.

Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.

Chung HW, Lim JB, Jang S, Lee KJ, Park KH, Song SY.

Cancer Sci. 2012 Sep;103(9):1714-21. doi: 10.1111/j.1349-7006.2012.02358.x. Epub 2012 Jul 30.

PMID:
22703527
20.

Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma.

Cui Y, Tian M, Zong M, Teng M, Chen Y, Lu J, Jiang J, Liu X, Han J.

Pancreatology. 2009;9(1-2):89-98. doi: 10.1159/000178879. Epub 2008 Dec 12.

PMID:
19077459
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk